← Back
Data updated: Jun 28, 2026
MISSION PHARMACAL
Generics Pharmaceuticals
MISSION PHARMACAL is a generic drug manufacturer with 4 FDA-approved products.
2011
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
MISSION PHARMACAL's Key Drugs
MISSION PHARMACAL's core commercial portfolio centers on THIOLA EC — its most strategically important drugs approved in the last 15 years.
MISSION PHARMACAL's Recent FDA Approvals
New NDA/BLA approvals for MISSION PHARMACAL over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
MISSION PHARMACAL's Therapeutic Areas
Disease areas where MISSION PHARMACAL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
MISSION PHARMACAL Pipeline Snapshot
Active clinical trials for MISSION PHARMACAL across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • THIOLA EC leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2011-02-18
- Latest
- 2024-06-20
- Applications
- 4